Two Diabetes Drugs, One Powerful Punch: Real-World Data Reveal Semaglutide Plus SGLT2 Inhibitor Benefits

One of the largest real-world investigations of dual diabetes therapy ever conducted has delivered a striking verdict: when Chinese adults with type 2 diabetes took the blockbuster injectable semaglutide alongside an SGLT2 inhibitor pill, their blood sugar and cholesterol profiles improved significantly, and the combination proved as tolerable as semaglutide alone. The findings, published in Diabetes Therapy, come from a post hoc analysis of the SCHOLAR study, which mined a city-wide electronic health records database in Tianjin, China, covering 82 hospitals. Of 26,859 adults who started once-weekly subcutaneous semaglutide between January 2022 and February 2023, a remarkable 11,361 — 42.3 percent — were also prescribed an SGLT2 inhibitor such as empagliflozin, dapagliflozin, or canagliflozin within six months. That prevalence alone is newsworthy, because until now clinicians in China have had little real-world evidence about how often these two drug classes are actually combined, or what happens when they are.

The scientific logic behind pairing these medications is compelling. Semaglutide is a glucagon-like peptide 1 receptor agonist, or GLP-1RA: it mimics an intestinal hormone that amplifies insulin secretion when glucose levels are high, suppresses glucagon, slows gastric emptying, and dampens appetite. SGLT2 inhibitors work through an entirely different route — they block a transporter in the kidney’s proximal tubule that normally reabsorbs filtered glucose, flushing excess sugar out through the urine. Because the mechanisms do not overlap, researchers have long suspected additive or even synergistic effects on glycated hemoglobin (HbA1c), body weight, and cardiometabolic risk. Large randomized trials of both classes have independently demonstrated cardiovascular and kidney protection, and international guidelines now recommend agents with proven cardiovascular or renal benefit for people with type 2 diabetes who have, or are at risk of, cardiovascular disease or chronic kidney disease.

The new analysis quantified just how much the combination delivers in routine practice. Among participants with HbA1c measurements at both baseline and six months, the overall combined-treatment group achieved a mean HbA1c reduction of 0.64 percentage points (95 percent confidence interval −0.71 to −0.56; p < 0.0001). Those who stayed on semaglutide continuously for the full six months did better still, with a mean drop of 0.73 percentage points. The effect was most dramatic in people starting with poorly controlled diabetes: among those with baseline HbA1c of 7 percent or higher, the continuous-semaglutide subgroup saw a reduction of 1.20 percentage points, and the overall combined group 1.10 percentage points. Meanwhile, the share of participants achieving the widely used treatment target of HbA1c below 7 percent climbed from 37.8 percent at baseline to 55.1 percent at month six in the overall group, and from 38.8 percent to 58.2 percent among continuous semaglutide users.

The lipid results may prove just as consequential for long-term health. Over six months, mean total cholesterol fell by 0.16 mmol/L, low-density lipoprotein (LDL) cholesterol — the atherosclerosis-driving variety — by 0.17 mmol/L, and triglycerides by 0.16 mmol/L, all statistically significant, while high-density lipoprotein (HDL) cholesterol rose by 0.03 mmol/L. Because people with type 2 diabetes face substantially elevated risks of cardiovascular disease and chronic kidney disease compared with the general population, these parallel improvements in glucose handling and blood fats matter. Previous studies of combined GLP-1RA and SGLT2 inhibitor therapy have reported lower rates of major adverse cardiovascular events, cardiovascular mortality, and heart failure hospitalization compared with either drug class alone, and the lipid shifts observed here are consistent with that cardioprotective narrative.

Safety findings will reassure clinicians weighing the risks of polypharmacy. Gastrointestinal complaints were the most common adverse events — constipation in 1.51 percent of participants, abdominal discomfort in 0.91 percent, and diarrhea in 0.80 percent — a pattern that mirrors the tolerability profile of subcutaneous semaglutide reported in the broader SCHOLAR population, in the international SURE real-world program, and in the randomized SUSTAIN 9 and SUSTAIN China trials. Hypoglycemia, a feared complication of intensifying glucose-lowering therapy, was not flagged as a prominent issue, which is plausible mechanistically: both drug classes lower glucose in glucose-dependent or glucose-independent ways that do not directly force insulin release the way sulfonylureas do.

Who received the combination is as revealing as how they fared. Cardiovascular comorbidities were strikingly prevalent in the combined-treatment group: 80.2 percent had cardiovascular disease, 65.9 percent coronary heart disease, and 63.4 percent hypertension — all higher than in the full SCHOLAR population. Notably, nearly a third of the combination group already had HbA1c below 7 percent at baseline, suggesting that physicians were prescribing the pair not primarily to rescue failing glucose control but to protect hearts and kidneys in high-risk patients, exactly as guidelines intend. The authors also observed a subtle prescribing pattern: 60.4 percent of the combination group were male, slightly above the 57.3 percent male share in the full SCHOLAR cohort. Because female sex is one of the strongest predictors of genital infections with SGLT2 inhibitors, the imbalance may reflect clinicians deliberately steering the pill class away from women at higher risk of that side effect.

How do these numbers stack up against the gold standard of randomized trials? In SUSTAIN 9, semaglutide added to existing SGLT2 inhibitor therapy cut HbA1c by 1.5 percent at week 30, and SUSTAIN China showed reductions of 1.5 to 1.8 percent with semaglutide 0.5 mg and 1.0 mg respectively. A meta-analysis of eight randomized trials of GLP-1RA plus SGLT2i combination therapy reported a pooled HbA1c reduction of 0.77 percent, and real-world studies in Spain and the United States have documented reductions of roughly 1.1 percent. The Tianjin figures are more modest, and the authors point to a likely explanation: in a real-world database study, dose information was unavailable, adherence is unmonitored, and the ±3-month assessment window reflects the messiness of routine care rather than the tight protocols of a phase 3 trial. Encouragingly, participants who refilled semaglutide without a gap of more than 45 days — the study’s definition of continuous treatment — achieved larger HbA1c reductions than those who did not, reinforcing the message that consistent adherence may be the single biggest lever on real-world glycemic outcomes.

The study’s international context is also instructive. In the SURE program of prospective observational studies across multiple countries, 27.5 percent of participants overall were taking an SGLT2 inhibitor when they started semaglutide — but the range was enormous, from 38.6 percent in the United Kingdom and 27.7 percent in Denmark/Sweden down to 9.8 percent in Italy and a mere 0.2 percent in France. Regional prescribing guidelines, insurance coverage, and medical policy evidently shape combination therapy far more than biology does. Against that backdrop, the 42.3 percent combination rate in Tianjin is high, hinting that Chinese clinicians have embraced guideline-directed dual cardiometabolic therapy with enthusiasm, at least within this large urban health system.

Honest caveats accompany the enthusiasm. This was a post hoc, single-arm analysis of retrospective, de-identified records, not a randomized comparison, so the results show association rather than causation, and unmeasured confounding cannot be excluded. SGLT2 inhibitor use was defined as at least one prescription within six months of starting semaglutide, meaning some participants may not have taken the pill class throughout follow-up. Only a minority of participants had HbA1c or lipid values recorded at both time points — 1,855 of 11,361 for HbA1c — which could bias results toward patients who were more engaged with care. Body weight and blood pressure changes could not be analyzed at all due to sparse and unreliable recording, a notable gap given evidence that the combination may have additive effects on weight loss. The authors also caution that cardiovascular and kidney outcomes themselves were not comprehensively assessed here, though other studies, including the FLOW trial showing semaglutide’s renal benefits with or without baseline SGLT2i use, are filling that void.

Even with those limitations, the analysis lands at a pivotal moment. Semaglutide has become a global phenomenon, and SGLT2 inhibitors are among the most guideline-endorsed pills in cardiometabolic medicine, yet rigorous real-world data on their combination — especially in Chinese populations, who represent a vast share of the world’s diabetes burden — have been scarce. The Tianjin data suggest that the pairing is already mainstream in Chinese practice, that it meaningfully improves both glycemic control and lipid profiles within six months, and that it does so without a safety penalty beyond the familiar gastrointestinal effects of GLP-1 receptor agonists. For the millions of people with type 2 diabetes and coexisting cardiovascular or kidney disease, the message is that two well-understood drugs attacking glucose from two different directions can deliver more than either alone — provided patients can stay on treatment. As the authors conclude, prospective research on weight, blood pressure, and hard cardiovascular and renal endpoints in Chinese populations should be the next frontier for this increasingly popular therapeutic duo.

Subject of Research: Real-world effectiveness and safety of combined semaglutide and SGLT2 inhibitor therapy in Chinese adults with type 2 diabetes

Article Title: Combined Semaglutide and Sodium–Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis

Article References: Wang, S., Dong, B., & Shen, Z. (2026). Combined Semaglutide and Sodium–Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis. Diabetes Therapy. https://doi.org/10.1007/s13300-026-01915-y

Image Credits: AI Generated

DOI: 10.1007/s13300-026-01915-y

Keywords: semaglutide, SGLT2 inhibitors, type 2 diabetes, HbA1c, GLP-1 receptor agonists, combination therapy, real-world evidence, cardiovascular disease, lipid profile, China, SCHOLAR study, Diabetes Therapy